These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20856685)

  • 1. Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.
    Gasperini C; Ruggieri S; Pozzilli C
    Ther Clin Risk Manag; 2010 Sep; 6():391-9. PubMed ID: 20856685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC
    J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
    Leist TP; Vermersch P
    Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K; Sipe JC
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cladribin. Development of an oral formulation for the treatment of multiple sclerosis].
    Hartung HP; Kieseier BC; Aktas O
    Nervenarzt; 2010 Feb; 81(2):194-202. PubMed ID: 20127230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.
    Schreiner TL; Miravalle A
    J Cent Nerv Syst Dis; 2012; 4():1-14. PubMed ID: 23650463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.
    Girouard N; Soucy N
    Patient Prefer Adherence; 2011 Feb; 5():101-8. PubMed ID: 21448467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis].
    Zhuravleva MV; Davydovskaya MV; Luchinina EV; Shelekhova TV; Kurguzova DO; Serebrova SY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(8):148-153. PubMed ID: 32929938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
    Murphy JA; Harris JA; Crannage AJ
    Neuropsychiatr Dis Treat; 2010 Oct; 6():619-25. PubMed ID: 20957121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging oral drugs for multiple sclerosis.
    Gasperini C; Cefaro LA; Borriello G; Tosto G; Prosperini L; Pozzilli C
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):465-77. PubMed ID: 18764723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of multiple sclerosis.
    Meuth SG; Bittner S; Wiendl H
    Acta Neuropsychiatr; 2009 Jun; 21 Suppl 2():27-34. PubMed ID: 25384864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.
    Giovannoni G; Mathews J
    Neurol Ther; 2022 Jun; 11(2):571-595. PubMed ID: 35318617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.
    Thöne J; Ellrichmann G
    Drug Healthc Patient Saf; 2013; 5():37-47. PubMed ID: 23459383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.